Showing results (111-120 of 159) with videos related to

Sort By:
Pageof 16
Hepatology International|January 9, 2021
Phase 2 trial comparing sorafenib, pravastatin, their combination or supportive care in HCC with Child-Pugh B cirrhosisJean-Frédéric Blanc, Faiza Khemissa, Jean-Pierre Bronowicki, et al.
JHEP Reports : Innovation in Hepatology|February 3, 2025
First-line chemotherapy with selective internal radiation therapy for intrahepatic cholangiocarcinoma: The French ACABi GERCOR PRONOBIL cohortNicolas Adamus, Julien Edeline, Julie Henriques, et al.
Annals of Hepatology|December 26, 2025
Effect of pembrolizumab on viral hepatitis load and transaminases in advanced hepatocellular carcinomaStephen Lam Chan, Richard S Finn, Julien Edeline, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|June 7, 2024
Ampullary tumors: French Intergroup Clinical Practice Guidelines for diagnosis, treatments and follow-up (TNCD, SNFGE, FFCD, UNICANCER, GERCOR, SFCD, SFED, ACHBT, AFC, SFRO, RENAPE, SNFCP, AFEF, SFP, SFR)Vincent Hautefeuille, Nicolas Williet, Anthony Turpin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 2, 2026
Pembrolizumab Monotherapy in Sorafenib-Treated and Treatment-Naive Advanced Hepatocellular Carcinoma: Long-Term Follow-Up of Open-Label, Phase 2 KEYNOTE-224 StudyRichard S Finn, Masatoshi Kudo, Ivan Borbath, et al.
Clinics and Research in Hepatology and Gastroenterology|June 25, 2020
Liver transarterial chemoembolization and sunitinib for unresectable hepatocellular carcinoma: Results of the PRODIGE 16 studyAnthony Turpin, Thierry de Baere, Alexandra Heurgué, et al.
Therapeutic Advances in Medical Oncology|October 6, 2025
Management of biliary tract cancers in elderly patients: a French multicenter retrospective study (PRONOBIL-ACABi)Marine Valery, Julien Edeline, Julie Henriques, et al.
Liver Cancer|October 30, 2023
Pembrolizumab as Second-Line Therapy for Advanced Hepatocellular Carcinoma: Longer Term Follow-Up from the Phase 3 KEYNOTE-240 TrialPhilippe Merle, Masatoshi Kudo, Julien Edeline, et al.
The Lancet. Gastroenterology & Hepatology|June 22, 2026
Addition of ipilimumab to atezolizumab plus bevacizumab in advanced hepatocellular carcinoma (PRODIGE 81-FFCD 2101-TRIPLET HCC): phase 2 results from a randomised, multicentre, open-label, phase 2-3 trialPhilippe Merle, Jean-Frederic Blanc, Karine Le Malicot, et al.
International Journal of Cancer|September 14, 2016
Independent association of PD-L1 expression with noninactivated VHL clear cell renal cell carcinoma-A finding with therapeutic potentialSolène-Florence Kammerer-Jacquet, Laurence Crouzet, Angélique Brunot, et al.
Pageof 16